NantKwest, Inc. (filing text identifies NantKwest, not ImmunityBio)
Business context and period. This is NantKwest’s unaudited Form 10-Q for the quarter and six months ended June 30, 2015. The company was a clinical-stage biotechnology business developing natural-killer-cell immunotherapies; it had no approved products or product-sale revenue. It changed its name from Conkwest to NantKwest in July 2015. The supplied request metadata names ImmunityBio, so the issuer mapping should be checked.
Financial results and position
| Metric | Three months ended June 30, 2015 | Six months ended June 30, 2015 |
|---|---|---|
| Revenue | $0.091 million | $0.211 million |
| Research and development | $1.745 million | $2.348 million |
| Selling, general and administrative | $82.429 million | $114.023 million |
| Operating loss | $84.083 million | $116.160 million |
| Net loss | $84.581 million | $117.406 million |
| Basic and diluted loss per share | $1.29 | $1.85 |
At June 30, 2015, cash and cash equivalents were $120.437 million, total current assets $120.870 million, total assets $132.557 million, total liabilities $6.039 million, and stockholders’ equity $126.518 million. No notes payable were outstanding. The six-month cash-flow statement reports $10.042 million used in operations, $2.573 million used in investing, and $73.948 million provided by financing; cash increased $61.333 million. Gross margin is not meaningfully reported because revenue was minimal and the filing provides no clear gross-profit measure.
Changes versus prior comparable periods
- Q2 revenue fell $33,000 year over year; first-half revenue declined $199,000. Management cited the June spinout of most non-clinical licensing activity and the nonrecurrence of a 2014 commercial license fee.
- Q2 operating expenses rose $82.879 million year over year, while first-half expenses rose $113.895 million. The increase was overwhelmingly associated with stock-based compensation and other costs tied to the Inex Bio transaction, alongside higher R&D spending.
- Net loss increased from $1.396 million to $84.581 million in Q2, and from $2.554 million to $117.406 million for the first half. First-half stock-based compensation was $104.564 million, making the reported loss substantially larger than operating cash use.
- Cash rose from $59.104 million at December 31, 2014 to $120.437 million at June 30, 2015, chiefly due to equity financing and warrant exercises.
Outlook, commentary, and risks
- Management expected operating losses and R&D and administrative expenses to increase as clinical development, manufacturing preparation, hiring, and public-company costs expanded. It did not expect product revenue for at least several years, if ever.
- Management said June-quarter cash alone was expected to fund operations and capital needs for at least 12 months, while warning it might not fund the company through commercialization. Subsequent financing materially increased liquidity: the July IPO generated approximately $225.5 million net of underwriting discounts but before offering expenses, and a concurrent private placement generated $17.0 million. The company reported $365.0 million cash at August 31, 2015.
- The company spun out its non-clinical testing and diagnostic business to Brink Biologics and its veterinary oncology business to Coneksis on June 9, distributing each entity’s shares to stockholders. It expected only nominal future revenue from the transferred non-clinical licenses.
- The Inex Bio reacquisition involved CEO- and director-affiliated parties. The filing recorded $22.747 million of stock-based compensation and $5.419 million of cash compensation associated with the transaction; management’s discussion also describes $6.4 million of cash consideration paid to the CEO and a director. This related-party accounting and amount should be reviewed.
- On September 2, 2015, after quarter-end, a federal district court granted the USPTO summary judgment in a patent dispute concerning certain NK-92 methods-of-use claims. The company had not decided whether to appeal and warned the outcome could affect future revenue.
- Disclosure controls were assessed as ineffective at June 30 because of material weaknesses: excessive financial-processing responsibility concentrated in the CFO and insufficient finance staffing for complex transactions. Remediation was underway but not complete.
- Key risks include early-stage clinical and regulatory uncertainty, manufacturing scale-up and cell-storage challenges, dependence on collaborators, intellectual-property risks, related-party conflicts, and reliance on future financing. The CEO and affiliates held a controlling interest, and the company disclosed significant dilution potential from outstanding options, warrants, and future equity awards.
Most important facts for investors to verify
- Confirm issuer identity: the filing is for NantKwest, Inc.; the request metadata says ImmunityBio.
- Review the Inex Bio acquisition’s related-party terms, valuation assumptions, compensation accounting, and the differing cash-compensation descriptions.
- Track the USPTO case outcome, any appeal, and the effect on the company’s patent coverage and licensing prospects.
- Reconcile post-quarter financing proceeds, offering expenses, August cash, and the company’s stated runway against planned development and facility costs.
- Assess the magnitude and vesting of CEO/officer awards, warrants, options, and other potential share dilution.
- Monitor whether the disclosed internal-control weaknesses are remediated and whether subsequent filings report any accounting corrections.